e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Exacerbations of severe asthma in patients treated with mepolizumab
Rahul Shrimanker, Ian D. Pavord, Steve Yancey, Liam G. Heaney, Ruth H. Green, Peter Bradding, Beverley Hargadon, Chris E. Brightling, Andrew J. Wardlaw, Pranabashis Haldar
Source:
Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018
Journal Issue:
December
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Rahul Shrimanker, Ian D. Pavord, Steve Yancey, Liam G. Heaney, Ruth H. Green, Peter Bradding, Beverley Hargadon, Chris E. Brightling, Andrew J. Wardlaw, Pranabashis Haldar. Exacerbations of severe asthma in patients treated with mepolizumab. Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Evolution of patients with severe asthma treated with mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 526s
Year: 2006
Severe outcomes of COVID-19 among patients with COPD and asthma
Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020
Year: 2021
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Exacerbations of asthma and treatment
Source: International Congress 2018 – PG1 Asthma and chronic obstructive pulmonary disease
Year: 2018
Montelukast as add-on therapy in severe noninfectious COPD exacerbations
Source: Eur Respir J 2003; 22: Suppl. 45, 241s
Year: 2003
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Oral montelukast in patients with acute severe asthma
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Markers of T2-inflammation in patients with severe asthma and concomitant COPD
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020
Real-life treatment of severe eosinophilic asthma with mepolizumab
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Ceruloplasmine efficacy in patients with asthma exacerbations
Source: Annual Congress 2011 - Novel mechanisms in lung injury
Year: 2011
Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD
Source: Eur Respir J 2013; 41: 993-995
Year: 2013
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations
Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019
Year: 2019
Predictors of severe exacerbations in patients with moderate and severe asthma
Source: International Congress 2018 – Determinants and monitoring of asthma control
Year: 2018
Exacerbations of COPD and treatment
Source: International Congress 2018 – PG1 Asthma and chronic obstructive pulmonary disease
Year: 2018
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept